NCT03413995View on ClinicalTrials.gov

Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations

PHASE2CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

September 10, 2018

Primary Completion Date

November 8, 2023

Study Completion Date

September 12, 2024

Conditions

Prostate Cancer Metastatic

Interventions

DRUG

Rucaparib

Continuous dosing

Trial Locations (2)

10065

Weill Cornell Medical College, New York

21205

Johns Hopkins Hospital, Baltimore

Sponsors

Collaborators (1)

Clovis Oncology, Inc.

All Listed Sponsors

collaborator

Clovis Oncology, Inc.

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT03413995 - Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations | Biotech Hunter | Biotech Hunter